This is a single arm, open-label, multi-center, phase II feasibility study to deliver point-of-care manufactured CD19-directed CAR T-cell therapy to patients with relapsed / refractory B-lineage leukaemia / lymphoma.~The study consists of the following phases:~Screening phase: Eligibility; enrolment~Preparatory phase: Bridging therapy (if required); leukapheresis; CAR T manufacturing; lymphodepletion.~Treatment phase: Infusion of single dose of anti-CD19 CAR T-cells~Follow-up Phase: Efficacy and safety monitoring up to 24 months
The purpose of this study is to describe feasibility of delivering point-of-care manufactured CD19-directed CAR T-cell therapy to patients with relapsed/ refractory B-lineage leukaemia/ lymphoma.